PURPOSE: 3'-[F-18]Fluoro-3'-deoxythymidine (FLT) is an analog of thymidine that is being developed for imaging cellular proliferation. The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity. PROCEDURES: Twelve patients with gliomas with either recurrence or suspected radionecrosis were imaged with FLT. Before and at several time points after imaging, subjects underwent general physical and neurological examinations with review of systems and tests of hematologic, hepatic, renal, and several other metabolic parameters. Vital signs and electrocardiograms were monitored during and after the imaging session. RESULTS: There were no significant adverse effects from FLT injected at a dose of 0.07 mCi/kg (maximum of 5 mCi) at specific activities of 1.25 Ci/micromol or higher. The FLT mass administered for imaging was 0.0001% to 0.0009% of the least toxic cumulative dose administered in clinical trials of FLT as an antiretroviral agent. CONCLUSIONS: FLT is a safe radiotracer for quantifying proliferation in the human cancer setting.
PURPOSE:3'-[F-18]Fluoro-3'-deoxythymidine (FLT) is an analog of thymidine that is being developed for imaging cellular proliferation. The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity. PROCEDURES: Twelve patients with gliomas with either recurrence or suspected radionecrosis were imaged with FLT. Before and at several time points after imaging, subjects underwent general physical and neurological examinations with review of systems and tests of hematologic, hepatic, renal, and several other metabolic parameters. Vital signs and electrocardiograms were monitored during and after the imaging session. RESULTS: There were no significant adverse effects from FLT injected at a dose of 0.07 mCi/kg (maximum of 5 mCi) at specific activities of 1.25 Ci/micromol or higher. The FLT mass administered for imaging was 0.0001% to 0.0009% of the least toxic cumulative dose administered in clinical trials of FLT as an antiretroviral agent. CONCLUSIONS:FLT is a safe radiotracer for quantifying proliferation in the humancancer setting.
Authors: Mark Muzi; Alexander M Spence; Finbarr O'Sullivan; David A Mankoff; Joanne M Wells; John R Grierson; Jeanne M Link; Kenneth A Krohn Journal: J Nucl Med Date: 2006-10 Impact factor: 10.057
Authors: E Matthes; C Lehmann; D Scholz; M von Janta-Lipinski; K Gaertner; H A Rosenthal; P Langen Journal: Biochem Biophys Res Commun Date: 1987-10-14 Impact factor: 3.575
Authors: C Flexner; C van der Horst; M A Jacobson; W Powderly; F Duncanson; D Ganes; P A Barditch-Crovo; B G Petty; P A Baron; D Armstrong Journal: J Infect Dis Date: 1994-12 Impact factor: 5.226
Authors: Maxim A Moroz; Tatiana Kochetkov; Shangde Cai; Jiyuan Wu; Mikhail Shamis; Jayasree Nair; Elisa de Stanchina; Inna Serganova; Gary K Schwartz; Debabrata Banerjee; Joseph R Bertino; Ronald G Blasberg Journal: Clin Cancer Res Date: 2011-01-18 Impact factor: 12.531
Authors: Michael S Enslow; Lauren V Zollinger; Kathryn A Morton; Regan I Butterfield; Dan J Kadrmas; Paul E Christian; Kenneth M Boucher; Marta E Heilbrun; Randy L Jensen; John M Hoffman Journal: Clin Nucl Med Date: 2012-09 Impact factor: 7.794
Authors: Alexander M Spence; Mark Muzi; Jeanne M Link; Finbarr O'Sullivan; Janet F Eary; John M Hoffman; Lalitha K Shankar; Kenneth A Krohn Journal: Mol Imaging Biol Date: 2009-03-27 Impact factor: 3.488
Authors: Sanjay Chandrasekaran; Andrew Hollander; Xiangsheng Xu; Joseph L Benci; James J Davis; Jay F Dorsey; Gary Kao Journal: ScientificWorldJournal Date: 2013-04-04
Authors: Kevin P Horn; Jeffrey T Yap; Neeraj Agarwal; Kathryn A Morton; Dan J Kadrmas; Britney Beardmore; Regan I Butterfield; Kenneth Boucher; John M Hoffman Journal: Cancer Imaging Date: 2015-09-03 Impact factor: 3.909